

CE₁₄₃₄

nano
Empowering Clinicians, Transforming Lives

TECHNICAL SPECIFICATIONS

Available Stent Length (mm)	8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 50, 52
Available Stent Diameter (mm)	2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 4.50
Models	6 Cell design: 2.00, 2.25, 2.50, 2.75, 3.00 mm vessel wall 8 Cell design: 3.50, 4.00, 4.50 mm vessel wall
Stent Material	A medical grade L605 Cobalt Chromium alloy
Design	Uniform sinusoidal cell design
Stent Strut thickness	65 µm
Drug	Sirolimus
Drug Dose	1.33 µg/mm ²
Polymers	Biodegradable Polymer based matrix

ORDERING INFORMATION OF NOVUS CORONARY STENT SYSTEM

Stent Diameter (mm)	Stent Length (mm)												
	8	12	16	20	24	28	32	36	40	44	48	50	52
2.00	NV2.0008	NV2.0012	NV2.0016	NV2.0020	NV2.0024	NV2.0028	NV2.0032	NV2.0036	NV2.0040	NV2.0044	NV2.0048	NV2.0050	NV2.0052
2.25	NV2.2508	NV2.2512	NV2.2516	NV2.2520	NV2.2524	NV2.2528	NV2.2532	NV2.2536	NV2.2540	NV2.2544	NV2.2548	NV2.2550	NV2.2552
2.50	NV2.5008	NV2.5012	NV2.5016	NV2.5020	NV2.5024	NV2.5028	NV2.5032	NV2.5036	NV2.5040	NV2.5044	NV2.5048	NV2.5050	NV2.5052
2.75	NV2.7508	NV2.7512	NV2.7516	NV2.7520	NV2.7524	NV2.7528	NV2.7532	NV2.7536	NV2.7540	NV2.7544	NV2.7548	NV2.7550	NV2.7552
3.00	NV3.0008	NV3.0012	NV3.0016	NV3.0020	NV3.0024	NV3.0028	NV3.0032	NV3.0036	NV3.0040	NV3.0044	NV3.0048	NV3.0050	NV3.0052
3.50	NV3.5008	NV3.5012	NV3.5016	NV3.5020	NV3.5024	NV3.5028	NV3.5032	NV3.5036	NV3.5040	NV3.5044	NV3.5048	NV3.5050	NV3.5052
4.00	NV4.0008	NV4.0012	NV4.0016	NV4.0020	NV4.0024	NV4.0028	NV4.0032	NV4.0036	NV4.0040	NV4.0044	NV4.0048	NV4.0050	NV4.0052
4.50	NV4.5008	NV4.5012	NV4.5016	NV4.5020	NV4.5024	NV4.5028	NV4.5032	NV4.5036	NV4.5040	NV4.5044	NV4.5048	NV4.5050	NV4.5052

nano
Empowering Clinicians, Transforming Lives

Registered Office & Factory Address:

Nano Therapeutics Pvt. Ltd.
Plot No. D-54/2,
Hojiwala Industrial Estate,
Road No. 23, Near Gate No. 3,
Sachin Palsana Highway,
Sachin, Surat - 394 230,
Gujarat, India.

Tel: +91 88660 50898,
+91 90330 50853

Email: info@nano-therapeutics.net
Web: www.nano-therapeutics.net

Customer Care Helpline No:
1800 891 9097

Customer Care Email:
customercare@nano-therapeutics.net

EC REP

CMC Medical Devices & Drugs S.L.
C/Horacio Lengo N° 18,
CP 29006, Málaga, Spain,
Tel: +34 951 214 054
Fax: +34 952 330 100
Email: info@cmcmedicaldevices.com


NV77/AAV1AB0

Note: NOVUS is a trade mark of Nano Therapeutics Pvt. Ltd. Specifications are subject to revision, improvement and modifications (i) Endeavour Resolute (ii) Xience V (iii) Ultimaster (iv) Orsiro (v) Biomatrix & (vi) Biomime are the Registered Trademarks of Medtronic Inc., Abbott Group of Companies, Terumo Corporation, Biotronik SE, Biosensors International, Meril Life Sciences respectively. **Source:** The source of information is based on the product brochures/catalogue of respective brands.

NOVUS[®]
Sirolimus Eluting
Coronary Stent System


UNIQUE FEATURES OF NOVUS STENT

The next generation Ultra Thin Low Injury DES design, engineered to deliver Safety & Efficacy, with the proven efficacy of Sirolimus Drug, fully biodegradable polymers and Proprietary Electro-Polish CoCr platform.



ULTRA THIN STRUT THICKNESS OF NOVUS STENT

Ultra thin strut thickness increases flexibility, reduces stent profile, improves trackability and easy access of complex lesion sites. It reduces stent-induced arterial injury and inflammation and facilitate faster endothelialization




Strut shape and thickness are for graphical representation purpose - not to scale

STRUT THICKNESS & STRUT WIDTH


Width > Thickness = ↑ Radial Strength

Engineering beam strength equation demonstrates that a 30% increase in width would result in a 2x increase in resistance.




OVER EXPANSION

No Structural deformation on over expansion (upto 5.00 mm) of the NOVUS Stent Platform shows high resistance against arterial pressure and radial force.



DRUG RELEASE KINETICS



Novus has proven drug release kinetics. Initial burst release of Sirolimus followed by sustained release upto 40 days results in optimum intake of the drug and faster endothelialization.

EXCEPTIONAL SAFETY OF NOVUS STENT



COMPARISON BETWEEN SES PMS AND OTHER DES

Stent Name	Mace	Late loss (mm)	Cardiac death	TLR
SES PMS (6 month) (n=200)	1.50%	0.10 (at 6 month)	0.50%	1.00%
SES PMS (1 year) (n=175)	1.71%	0.10 (at 6 month)	0.57%	1.14%
Xience V, spirit II (n=223) (1 year)	2.7%	0.19 (at 6 months)	0%	1.8%
Xience V, spirit II (n=223) (2 year)	6.4%	0.19 (at 6 months)	0.5%	3.7%
Endeavour resolute (n=130) (1 year)	8.5%	0.22 (at 9 months)	0.80%	0.8%
Biomatrix (80 biomatrix subjects) (6 month)	3.8%	0.19 (at 6 months)	0%	1.3%
Biomatrix (80 biomatrix subjects) (1 year)	5.1%	0.19 (at 6 months)	NA	0.8%
Biomime (n=242) (1 year)	5.7%	0.15 (at 8 months)	0.50%	4.7%

Source: Chandra P., Kumar T. Indian Heart J. 2014;66(6):682-685